The estimated Net Worth of Gilmore Neil O'neill is at least $46.3 Milion dollars as of 4 September 2024. Mr. neill owns over 1,555 units of Sarepta Therapeutics Inc stock worth over $40,279,024 and over the last 6 years he sold SRPT stock worth over $867,088. In addition, he makes $5,168,110 as Executive Vice President a R&D and Chief Medical Officer at Sarepta Therapeutics Inc.
Sign up
Mr. Neill SRPT stock SEC Form 4 insiders trading
Gilmore has made over 4 trades of the Sarepta Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 1,555 units of SRPT stock worth $5,318 on 4 September 2024.
The largest trade he's ever made was selling 77,824 units of Sarepta Therapeutics Inc stock on 2 March 2024 worth over $733,102. On average, Gilmore trades about 5,448 units every 25 days since 2018. As of 4 September 2024 he still owns at least 313,724 units of Sarepta Therapeutics Inc stock.
You can see the complete history of Mr. neill stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gilmore O'Neill biography
Gilmore O'Neill is Executive Vice President, R&D and Chief Medical Officer of the Company. Dr. O’Neill has served as our Chief Medical Officer from June 2018. Prior to this appointment, Dr. O’Neill served as the Senior Vice President, Late Stage Clinical Development of Biogen Inc. from November 2016 to June 2018. At Biogen, Dr. O’Neill also served as Senior Vice President, Drug Innovation Units from October 2015 to November 2016. From June 2014 to October 2015, Dr. O’Neill served as Vice President, MS Franchise & Head, Multiple Sclerosis R&D at Biogen. Prior to this role, Dr. O’Neill served in numerous roles at Biogen since he joined the company in April 2003, including Vice president, Global Neurology Clinical Development, Vice president, Global Late Stage Clinical Development and Vice president, Experimental Neurology (Early Stage). Dr. O’Neill is licensed to practice medicine in the state of Massachusetts. He is a member of the American Academy of Neurology and a board-certified neurologist (ABPN). Dr. O’Neill is formerly Chief Resident in Neurology at the Massachusetts General Hospital (MGH) and served, until recently, as a Clinical Instructor in Neurology at Harvard Medical School. From 1997 to 2015, Dr. O’Neill served as a clinical instructor in neurology at Harvard Medical School. He also serves on the board of directors of the Massachusetts Biotechnology Council (MassBio). Dr. O’Neill has maintained his clinical appointment at the MGH with a sub-specialty interest in neuromuscular diseases and inherited leukodystrophies. Dr. O’Neill received a Bachelor of Medicine degree from University College Dublin and a Master of Medical Sciences degree from Harvard University.
What is the salary of Gilmore Neill?
As the Executive Vice President a R&D and Chief Medical Officer of Sarepta Therapeutics Inc, the total compensation of Gilmore Neill at Sarepta Therapeutics Inc is $5,168,110. There are no executives at Sarepta Therapeutics Inc getting paid more.
How old is Gilmore Neill?
Gilmore Neill is 55, he's been the Executive Vice President a R&D and Chief Medical Officer of Sarepta Therapeutics Inc since 2018. There are 12 older and 5 younger executives at Sarepta Therapeutics Inc. The oldest executive at Sarepta Therapeutics Inc is Hans Wigzell, 82, who is the Independent Director.
What's Gilmore Neill's mailing address?
Gilmore's mailing address filed with the SEC is C/O EDITAS MEDICINE, INC., 11 HURLEY ST., CAMBRIDGE, MA, 02141.
Insiders trading at Sarepta Therapeutics Inc
Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry a M Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.
What does Sarepta Therapeutics Inc do?
sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
What does Sarepta Therapeutics Inc's logo look like?
Complete history of Mr. neill stock trades at Editas Medicine Inc, Sarepta Therapeutics Inc, Unity Biotechnology Inc a Aptinyx Inc
Sarepta Therapeutics Inc executives and stock owners
Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Gilmore O'Neill,
Executive Vice President, R&D and Chief Medical Officer -
William Ciambrone,
Executive Vice President - Technical Operations -
David Howton,
Executive Vice President, General Counsel, Secretary -
Alexander Cumbo,
Executive Vice President and Chief Commercial Officer -
Douglas Ingram,
President, Chief Executive Officer, Director -
Douglas S. Ingram,
Pres, CEO & Director -
Dr. Gilmore O'Neill M.D.,
Exec. Officer -
Dr. Louise Rodino-Klapac Ph.D.,
Chief Scientific Officer and Head of R&D -
Ian Michael Estepan,
Exec. VP & CFO -
William F. Ciambrone,
Exec. VP of Technical Operations -
M. Kathleen Behrens,
Independent Chairwoman of the Board -
Richard Barry,
Independent Director -
Hans Wigzell,
Independent Director -
Claude Nicaise,
Independent Director -
Mary Gray,
Independent Director -
John Martin,
Independent Director -
Joseph Bratica,
Interim Principal Financial and Accounting Officer -
Dr. Diane L. Berry,
Sr. VP of Global Health Policy and Gov. & Patient Affairs -
Alison Nasisi,
Chief People Officer & VP -
Ryan E. Brown,
Sr. VP, Gen. Counsel & Corp. Sec. -
Mary Jenkins,
Sr. Mang. of Investor Relations -
Michael W Bonney,
Director -
Ben Gil Price,
Director -
Catherine Stehman Breen,
SVP, Chief Medical Officer -
Jayant Aphale,
SVP Technical Operations -
Jean Paul Kress,
Director -
William Alden Goolsbee,
Director -
Shamim Ruff,
SVP, Chief Regulatory Affairs -
Sandesh Mahatme,
EVP, CFO & CBO -
Guriqbal S. Basi,
SVP, Chief Scientific Officer -
Michael A Jacobsen,
VP of Finance and PAO -
Anthony Martignetti,
-
Nishan Garabedian Christopher,
President and CEO -
Anthony R Chase,
Director -
John Hodgman,
Director -
Arthur M Krieg,
SVP, Chief Scientific Officer -
Edward M. Md Kaye,
SVP & Chief Medical Officer -
Ian Michael Estepan,
Chief Financial Officer -
Ryan Edward Brown,
EVP, General Counsel -
Louise Rodino Klapac,
Head of R&D, CSO -
Bilal Arif,
Chief Tech Ops Officer -
Stephen Mayo,
-
Kathryn Jean Boor,
-
Dallan Murray,
Chief Customer Officer